News

Activating NRAS mutations occur in approximately 20% of melanomas, representing the second most common oncogenic driver mutation in melanoma after BRAF mutations. An unmet medical need remains for

The CheckMate -649 trial demonstrated statistically significant and clinically meaningful improvement in both the parameters for the Opdivo + chemotherapy arm compared to chemotherapy alone. The late-stage trial

The deal also allows Inflazome to secure additional contingent payments based on the achievement of certain predetermined milestones. Based in Dublin, Inflazome is engaged in the development of

Late-breaking, first-time study results showed that with 3.5 years of follow-up, adjuvant KEYTRUDA met the key secondary endpoint of distant metastasis-free survival (DMFS), reducing the risk of distant

The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on

The global trial called EV-301 compared PADCEV to chemotherapy in nearly 600 patients who had prior treatment with platinum-based chemotherapy and a PD-1/L1 inhibitor. Co-developed by the two

The vaccine candidate is being developed using Sanofi’s recombinant protein-based technology and GSK’s advanced adjuvant technology. Sanofi’s protein-based technology is currently used to produce an influenza vaccine. Both

Since inception in 2017, Eyevance develops and commercializes topical ophthalmic products targeting the ocular surface and anterior segment. Within this area of focus, Eyevance currently offers anti-inflammatory, anti-allergic,

The pharma major plans to advance the PCSK9 inhibitor programme into clinical development for dyslipidaemia and familial hypercholesterolemia in 2021. Dyslipidaemia is a condition in which there is